Deerfield

What Deerfield does

Deerfield Management Company, L.P. is a privately held, healthcare-dedicated investment firm registered as an adviser under the Investment Advisers Act of 1940, headquartered at 345 Park Avenue South, New York, with a regional office in Doha, Qatar. The firm operates a vertically integrated platform that combines multi-billion-dollar fund vehicles (notably the $1.4 billion Deerfield Private Design Fund V closed in August 2021 and the over-$600 million Healthcare Innovations Fund III closed in 2025) with an in-house company-building R&D engine called Deerfield Discovery and Development (3DC), a healthcare innovation campus (Cure®), an AI/data intelligence function (Deerfield Intelligence), and a medtech incubator (Deerfield Catalyst).

The 3DC engine advances early-stage therapeutics from scientific discovery through preclinical proof of concept and into the clinic, supported by state-of-the-art laboratory infrastructure housed at Cure including a cryo-electron microscope (engineered to damp New York City subway vibrations), NMR, flow cytometry, automated screening robots, and high-throughput mass spectrometry. Genscience, an affiliate capability, applies genetic evidence to drug target identification (work published in Nature). The Lab of the Future — a 6,000-square-foot automated facility at Cure leveraging AI, machine learning, and robotics — is being expanded with commercialization plans, supported by a $25 million New York State and Empire State Development grant awarded in March 2023.

Deerfield's business model generates revenue through management fees and performance-based compensation on its closed-end private investment funds, structured public finance and trading activity, and strategic/industrial partnership funding structures. It serves three primary customer segments: (1) private and public healthcare companies across the innovation lifecycle (therapeutics, medical devices, healthcare services, diagnostics, digital health); (2) academic research institutions via 20+ dedicated collaboration vehicles (e.g., Amethyst Innovations/NYU Langone, Bluefield Innovations/Johns Hopkins, Porter Alliance/Stanford, Lab1636/Harvard, Riverway Discoveries/Dana-Farber) typically with up to $130 million and 10-year commitments each; and (3) large industrial partners (Johnson & Johnson Innovation, Pfizer, Eli Lilly, Thermo Fisher, Illumina, Insilico Medicine, Charles River, Schrödinger, BioSymetrics, Relation Therapeutics, Coridea) for asset collaboration, potential acquisition, and shared infrastructure. Distribution also includes healthcare-services joint ventures with payers — Alo Solutions (Blue Cross Blue Shield of North Carolina) and Vanova Health (Horizon Blue Cross Blue Shield of New Jersey) — supporting independent physician practices.

Name

Deerfield

Legal name

Deerfield Management Company, L.P.

Website

https://deerfield.com

Company type

Private

Founded year

1994

Operating status

Operating

Headcount range

101–250 employees

Short description

Deerfield Management is a private healthcare investment firm that combines multi-billion-dollar fund vehicles with an in-house R&D engine (3DC), a New York-based innovation campus (Cure), and AI-driven intelligence to build and back therapeutics, medtech, and healthcare-services companies, plus a broad network of academic and industrial collaborations.

Ownership category

akta.pro rank

Product category

Healthcare Investment Management

NAICS

Portfolio Management and Investment Advice (52394), Portfolio Management and Investment Advice (523940)

SIC

Investment Advice (6282)

akta.pro primary industry

Equipment Financing / Leasing (Venture-backed) (FSANAIAE)

Keywords

• Healthcare investment
• Venture capital
• Drug discovery
• Medical research funding
• Private equity

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales, Others

Revenue model

1. Investment Management Fees: Deerfield is registered as an adviser under the Investment Advisers Act of 1940 and provides investment advisory services to a limited number of private investment vehicles, generating fees and other compensation disclosed in fund governing documents.
2. Deerfield Private Design Fund V ($1.4 billion): New $1.4-billion private investment fund providing customized solutions to private and public companies at all stages of innovation, generating recurring management and performance-based fees.
3. Healthcare Innovations Fund III (over $600 million): Closed healthcare venture fund investing in promising therapeutics, improvements to healthcare delivery, and paradigm-shifting technologies; generates management and incentive fees.
4. Structured Public Finance and Trading: Deerfield supports a diverse portfolio of private and public investments spanning therapeutics, medical devices, healthcare services, diagnostics, and digital health, including public structured finance and trading activities.
5. Strategic and Industrial Partnership Funding: Deerfield structures creative, flexible financial and operational support for partners, including collaboration agreements with biopharma and academic institutions and structured finance offerings.

Pricing tiers

Go-to-market motion4 records

Distribution channels7 records

Marketing channels8 records

Core offering

Deerfield Management is a privately held healthcare-focused investment firm that deploys flexible capital across all stages of healthcare innovation through dedicated private investment funds. It pairs its financial capital with an in-house R&D engine (3DC), a healthcare innovation campus (Cure) with state-of-the-art laboratory infrastructure, AI-driven intelligence, and an extensive academic and industrial collaboration network to build and scale healthcare companies. Revenue is generated through investment advisory services, management fees, and performance-based compensation on private investment vehicles.

Product overview

Deerfield Management Company, L.P. is a healthcare-focused investment firm operating a platform-plus-modules architecture. The core engine is Deerfield Discovery and Development (3DC), Deerfield's in-house R&D unit with bench scientists and industry veterans advancing early-stage therapeutics through preclinical proof of concept, complemented by its affiliate Cure, a New York City healthcare innovation campus housing lab space (cryo-EM, NMR, flow cytometry, automated screening robots, high-throughput mass spectrometry) and numerous life science and healthcare companies. Around this core, Deerfield offers: Deerfield Intelligence (AI, data, and market research); the Deerfield Foundation (philanthropy, including the AML Summit and ASH Peter Steelman Scholar Award); Deerfield Catalyst (a medtech incubator at Cure); physician enablement joint ventures Alo Solutions (with Blue Cross Blue Shield of North Carolina) and Vanova Health (with Blue Cross Blue Shield of New Jersey); a broad portfolio of therapeutics and medtech companies such as Neomorph, Nuvalent, and Cathworks; the Genscience genetics affiliate; the Lab of the Future automated drug discovery lab at Cure; investment vehicles including Healthcare Innovations Fund III and Private Design Fund V; the XSeed Awards grant program; and a wide network of named academic research collaborations (Amethyst Innovations, Bayfield Therapeutics, VeritaScience, Riverway Discoveries, Pinnacle Hill, Orchard Innovations, Lakeside Discovery, Lab1636, Hudson Heights Innovations, Harbor Discoveries, Great Lakes Discovery, Hyde Park Discovery, Four Points Innovation, Brookline Avenue Innovations, Blue Square Discoveries, Bluefield Innovations, Blackfan Circle Innovations, Ancora Innovation, Porter Alliance, and West Loop Innovations).

Differentiator

Problem solved

Functional benefit

Brands

• 3DC (Deerfield Discovery and Development): Company-building R&D engine that advances early-stage therapeutics from scientific discovery through preclinical proof of concept and into the clinic.
• Cure
• Genscience
• Deerfield Catalyst
• Deerfield Foundation
• Deerfield Intelligence

Products and services

• Deerfield Private Design Fund V A $1.4 billion private investment fund that provides customized financial and operational solutions to private and public healthcare companies at all stages of innovation. Generates management and performance-based fees.
• Healthcare Innovations Fund III A closed healthcare venture fund of over $600 million that invests in promising therapeutics, healthcare delivery improvements, and paradigm-shifting technologies. Generates management and incentive fees.
• Deerfield Discovery and Development (3DC) Deerfield's internal research and development engine where bench scientists and industry veterans collaborate to advance early-stage therapeutics from scientific discovery through preclinical proof of concept and into the clinic. Capabilities span translational biology, DMPK, chemistry, CMC, data science, genetics, in vitro pharmacology, clinical and regulatory, cell and gene therapy, biologics, and safety assessment. Offered to portfolio companies and biopharma partners.
• Cure Healthcare Innovation Campus A premier healthcare innovation ecosystem headquartered in New York City and an affiliate of Deerfield. Cure provides state-of-the-art research and business facilities, lab equipment including cryo-EM, NMR, flow cytometry, automated screening robots, and high-throughput mass spectrometry, plus expert content, mentoring, networking, and business services for health innovators.
• Deerfield Intelligence Drives healthcare technology and innovation forward with AI, data, and market research capabilities across the healthcare ecosystem. Supports the broader healthcare investment strategy.
• Deerfield Foundation New York City-based not-for-profit that advances innovative healthcare initiatives, including the annual AML Summit and ASH Peter Steelman Scholar Award, and annual grants to organizations in seven countries focused on children's health, accelerating innovation, and promoting equity.
• Deerfield Catalyst A medtech incubator at the Cure campus committed to developing transformational medical device solutions to improve patient outcomes and streamline care.
• Alo Solutions Healthcare services platform built by Deerfield in partnership with Blue Cross Blue Shield of North Carolina that enables independent physicians to manage the business of medicine.
• Vanova Health Built by Deerfield with Blue Cross Blue Shield of New Jersey (Horizon BCBS NJ) to provide essential tools and services supporting independent physician practices.
• Lab of the Future Next-generation 6,000-square-foot automated laboratory at the Cure campus, supported by a $25 million grant from New York State and Empire State Development, leveraging AI, machine learning, and robotics to accelerate early-stage drug discovery, with plans to expand and commercialize the technology.
• XSeed Awards Annual grant and ecosystem-access program run by Cure (Deerfield affiliate) that awards up to $250,000–$500,000 to underfunded and underrepresented NYC life science startups, with access to the Cure ecosystem.

Quantifiable outcome

• Lab of the Future: 6,000-square-foot automated lab leveraging AI/ML/robotics to improve speed, accuracy, and cost of drug development
• +3 more outcomes

Segments5 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability10 records

Feature7 records

Partnerships

42 partnerships are on record, tiered flagship and core.

• NuvalentflagshipStrategic or Co-development Partner · 10 June 2026Deerfield teamed up with Harvard professor and now-CEO James Porter to build Nuvalent, a company working to create precisely targeted therapies for patients with cancer. Deerfield Management announced portfolio company Nuvalent, Inc. to be acquired by GSK.
• METiS TechBioflagshipStrategic or Co-development Partner · 28 May 2026METiS TechBio entered into a strategic alliance with Deerfield to advance AI-driven protein therapeutics and in vivo immunotherapy. METiS subsequently listed on the Hong Kong Stock Exchange (7666.HK), raising over HKD 2.1 billion, with BlackRock among the cornerstone investors.
• Hospital for Special Surgery (HSS)flagshipStrategic or Co-development Partner · 13 November 2025HSS and Deerfield Management have joined forces in an alliance to amplify mobility in athletics, aging, and everyday life. The parties combine strengths in data, technology, and expertise to accelerate development of novel medical devices, AI-powered digital tools and services, therapeutics, and consumer technologies with a focus on musculoskeletal health and longevity.
• University of Chicago (Hyde Park Discovery)flagshipStrategic or Co-development Partner · 1 January 2025The University of Chicago and Deerfield Management launched Hyde Park Discovery to accelerate translation of research into life-saving treatments. Deerfield commits up to $130 million to support UChicago drug discovery and development.
• Washington University in St. Louis (VeritaScience)flagshipStrategic or Co-development Partner · 1 January 2024Washington University in St. Louis and Deerfield Management launched VeritaScience, a private R&D collaboration designed to advance the discovery, clinical development, and commercialization of promising therapeutic and diagnostic candidates.
• NYU Langone Health (Amethyst Innovations)flagshipStrategic or Co-development Partner · 1 June 2023NYU Langone Health and Deerfield Management launched Amethyst Innovations with up to $130 million to accelerate the commercialization of biomedical discoveries. Researchers at NYU Langone gain access to Deerfield's capital, infrastructure, and specialized resources to help advance novel therapeutics beyond the lab.
• InvitaecoreTechnology or Integration · 22 March 2023Invitae and Deerfield Management partnered to create novel therapeutics for rare diseases. The partnership harnesses genetic and clinical data from millions of patients tested at Invitae and Deerfield's expertise in drug discovery to address high unmet needs among rare disease patients.
• Cold Spring Harbor Laboratory (Harbor Discoveries)flagshipStrategic or Co-development Partner · 1 January 2023Cold Spring Harbor Laboratory and Deerfield Management launched Harbor Discoveries to advance new therapeutics. Deerfield commits up to $130 million over 10 years to support drug development efforts, along with functional expertise.
• BioSymetricscoreTechnology or Integration · 31 October 2022Deerfield Management and BioSymetrics partnered to discover and develop novel therapeutics. Collaboration to advance cardiology and neurology targets using phenomics and genomic data to improve human health.
• Moffitt Cancer Center (Bayfield Therapeutics)flagshipStrategic or Co-development Partner · 1 September 2022Moffitt Cancer Center and Deerfield Management launched Bayfield Therapeutics, a translational research alliance to accelerate the development of new therapeutics to treat cancer. Deerfield has committed up to $130 million over 10 years to the collaboration.
• Beth Israel Deaconess Medical Center (Brookline Avenue Innovations)flagshipStrategic or Co-development Partner · 1 September 2022BIDMC and Deerfield Management announced a research collaboration to accelerate the creation and development of therapeutics. Through Brookline Avenue Innovations, LLC, Deerfield has committed up to $130 million over 10 years plus scientific/operational support.
• IlluminaflagshipTechnology or Integration · 5 May 2022First-of-its-kind partnership to identify drug targets and accelerate novel therapy development using genomics and artificial intelligence, combining Illumina's genomics platforms with Deerfield's drug discovery expertise.
• Stanford University (Porter Alliance for Innovative Medicines)flagshipStrategic or Co-development Partner · 1 January 2022Deerfield and Stanford University created the Porter Alliance for Innovative Medicines, a collaboration to accelerate translational research into clinical therapeutics. Deerfield Management commits up to $130 million to support Stanford's innovative translational research.
• Baylor College of Medicine (Blue Square Discoveries)flagshipStrategic or Co-development Partner · 1 May 2021Deerfield and Baylor College of Medicine announced Blue Square Discoveries, a major research collaboration to advance promising therapeutics and support pharmaceutical research and discovery. Deerfield will fund up to $130 million and provide development expertise.
• Empire Discovery Institute (Empire-Deerfield Discovery & Development, ED3)flagshipStrategic or Co-development Partner · 1 April 2021Empire Discovery Institute (EDI) and Deerfield Management launched ED3 LLC. Deerfield commits up to $65 million over five years to fund translational research in collaboration with EDI.
• Dana-Farber Cancer Institute (Riverway Discoveries)flagshipStrategic or Co-development Partner · 1 February 2021Deerfield and Dana-Farber Cancer Institute announced the formation of a major translational research partnership, Riverway Discoveries, to accelerate the development of therapeutics and diagnostics for cancer.
• Boston Children's Hospital (Blackfan Circle Innovations)flagshipStrategic or Co-development Partner · 1 November 2020Boston Children's Hospital (largest NIH-funded pediatric research enterprise in the U.S.) and Deerfield announced Blackfan Circle Innovations, a major research collaboration intended to advance promising therapeutics that address unsolved medical needs.
• University of Michigan (Great Lakes Discovery)flagshipStrategic or Co-development Partner · 1 May 2020Deerfield and the University of Michigan announced Great Lakes Discovery, a partnership to commercialize therapeutic projects that hold promise in solving unmet medical needs.
• Duke University (Four Points Innovation)flagshipStrategic or Co-development Partner · 1 December 2019Deerfield and Duke University announced Four Points Innovation, a major research collaboration spearheaded by Duke's Office of Licensing & Ventures to accelerate preclinical development of new drugs.
• Columbia University (Hudson Heights Innovations)flagshipStrategic or Co-development Partner · 1 June 2019Deerfield and Columbia University announced the creation of Hudson Heights Innovations, a major research and development alliance intended to advance the translation of biomedical discoveries into transformative treatments.
• University of Illinois at Chicago (West Loop Innovations)flagshipStrategic or Co-development Partner · 1 April 2019Deerfield and the University of Illinois at Chicago established West Loop Innovations to help accelerate the commercialization of therapeutics developed at UIC.
• Harvard University (Lab1636)flagshipStrategic or Co-development Partner · 1 March 2019Deerfield and Harvard University announced a major strategic R&D alliance called Lab1636 to speed the development and translation of biomedical and life-science innovations into transformative treatments.
• Yeda Research and Development Company / Weizmann Institute of Science (Orchard Innovations)flagshipStrategic or Co-development Partner · 1 January 2019Deerfield and Yeda, the commercial arm of the Weizmann Institute of Science, announced an extensive translational research initiative — the first outside the U.S. for Deerfield — to catalyze transformative treatments toward clinical validation.
• University of North Carolina at Chapel Hill (Pinnacle Hill)flagshipStrategic or Co-development Partner · 1 October 2018Deerfield and the University of North Carolina at Chapel Hill launched Pinnacle Hill, LLC, a Deerfield company seeking to discover new medicines to address significant unmet medical needs.
• Northwestern University (Lakeside Discovery)flagshipStrategic or Co-development Partner · 1 May 2018Northwestern University and Deerfield Management launched Lakeside Discovery to accelerate translation of transformative biomedical technologies. Deerfield provides up to $65 million of targeted funding and development/operational expertise, overseen by a joint steering committee.
• Vanderbilt University (Ancora Innovation)flagshipStrategic or Co-development Partner · 1 April 2018Deerfield and Vanderbilt University launched Ancora Innovation, LLC, a Deerfield company that supports Vanderbilt's innovative life science research and leverages Deerfield's expertise in accelerating drug development.
• Broad Institute of MIT and HarvardflagshipStrategic or Co-development Partner · 1 October 2017Deerfield launched a partnership with the Broad Institute of MIT and Harvard, a highly integrated biomedical and genomic research center with more than three thousand scientists, to tackle serious unmet medical needs.
• Johns Hopkins University (Bluefield Innovations)flagshipStrategic or Co-development Partner · 1 October 2017Deerfield and Johns Hopkins University entered Bluefield Innovations, a collaboration designed to catalyze the development of early-stage therapeutics.
• Johnson & Johnson InnovationflagshipStrategic or Co-development PartnerJohnson & Johnson Innovation is among Deerfield's select industrial partnerships, providing access to innovation across drug discovery and development, medical technology incubation, and technology-enabled healthcare services, with potential access to high-quality and later-stage projects and additional financial resources.
• Eli LillyflagshipStrategic or Co-development PartnerEli Lilly is among Deerfield's select industrial partners for collaboration across drug discovery and development, with potential acquisition of projects in areas of partner interest and access to industrial-scale and quality resources.
• PfizerflagshipStrategic or Co-development PartnerPfizer is among Deerfield's select industrial partnerships for collaboration across drug discovery and development, offering potential acquisition of projects in areas of partner interest, access to high-quality and later-stage projects, and industrial-scale resources.
• Thermo Fisher ScientificflagshipStrategic or Co-development PartnerThermo Fisher Scientific is among Deerfield's select industrial partners for collaboration across drug discovery, medical technology incubation, and technology-enabled healthcare services.
• Insilico MedicinecoreStrategic or Co-development PartnerInsilico Medicine is among Deerfield's industrial partners, offering potential to accelerate speed of execution with expanded marginal workforce, access to seasoned experts, proprietary novel/emerging platforms, and ability to "buy in bulk" for multiple projects.
• Charles River LaboratoriescoreStrategic or Co-development PartnerCharles River Laboratories is among Deerfield's industrial partners, offering potential to accelerate speed of execution with expanded marginal workforce, access to seasoned experts, and proprietary novel/emerging platforms.
• SchrödingercoreStrategic or Co-development PartnerSchrödinger is among Deerfield's industrial partners, providing access to proprietary, novel, and emerging platforms across the R&D continuum.
• Relation TherapeuticscoreStrategic or Co-development PartnerRelation Therapeutics is among Deerfield's select industrial partnerships for collaboration across drug discovery and development.
• Blue Cross Blue Shield of North Carolina (Alo Solutions)coreStrategic or Co-development PartnerDeerfield partnered with Blue Cross Blue Shield of North Carolina to build Alo, a physician enablement platform that enables North Carolina physicians to manage the business of medicine.
• Horizon Blue Cross Blue Shield of New Jersey (Vanova Health)coreStrategic or Co-development PartnerDeerfield Management and Horizon Blue Cross Blue Shield of New Jersey launched a joint venture to support and sustain independent physicians through Vanova Health, which provides essential tools and services to support independent physician practices.
• Medtronic (Cathworks)coreStrategic or Co-development PartnerDeerfield worked with Medtronic to acquire and mature Cathworks prior to integration into Medtronic's core business.
• CorideacoreStrategic or Co-development PartnerCoridea and Deerfield partnered to accelerate medtech innovation with an Innovation Center housed at the Cure campus in New York City.
• Dana-Farber Cancer Institute (Neomorph)coreStrategic or Co-development PartnerDeerfield and Dana-Farber Cancer Institute investigators launched Neomorph to advance the development of innovative new medicines against "undruggable" targets.
• Deerfield Catalyst (Medtech Incubator)coreStrategic or Co-development PartnerDeerfield Catalyst is a medtech incubator at the Cure campus committed to developing transformational solutions to improve patient outcomes and streamline care.

Scale indicators11 records

Recent moves10 records

Expansion highlights7 records

Direct peers

• Foresite Capital: Healthcare- and technology-focused investment firm combining venture, growth, and public strategies, with an integrated approach comparable to Deerfield's Private Design and Healthcare Innovations funds.
• 5AM Ventures: Early-stage healthcare VC focused on translating academic and early-stage science into companies — directly comparable to Deerfield's academic collaboration strategy.
• Versant Ventures: Healthcare-focused VC that partners with entrepreneurs and academics to build therapeutics, medtech, and digital health companies, with a discovery engine approach similar to Deerfield's 3DC.
• OrbiMed: Healthcare-dedicated investment platform spanning venture, growth, and credit across therapeutics, medtech, and diagnostics — comparable to Deerfield's multi-stage healthcare investment strategy.
• RA Capital Management: Healthcare-dedicated investment firm running crossover and venture funds that combine capital with in-house scientific diligence and a tech-enabling research unit — directly comparable to Deerfield's capital-plus-3DC model.
• ARCH Venture Partners: Long-standing healthcare-focused VC that co-creates companies from university research, with deep academic partnership networks analogous to Deerfield's 20+ university collaboration vehicles.
• Atlas Venture: Early-stage healthcare VC that builds companies from academic science, comparable to Deerfield's company-building approach through 3DC and named university vehicles.

Emerging players

• BridgeBio Pharma: Genetically driven drug discovery and development company that partners with academic institutions to translate discoveries into medicines — overlaps with Deerfield's genetic-evidence approach via Genscience and academic collaboration model.

Broad incumbents

• Bain Capital Life Sciences: Healthcare-focused investment platform within Bain Capital investing across therapeutics, medtech, and healthcare services at venture through growth stages — comparable in multi-stage healthcare breadth to Deerfield.
• New Enterprise Associates (NEA): Large multi-stage investment firm with a dedicated healthcare practice investing across therapeutics, medtech, and services — broader in mandate than Deerfield but overlapping in healthcare-dedicated deal flow.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries5 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments345 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Deerfield